Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.eris.co.in | |
Market Cap | 9,294.77 Cr. | |
Enterprise Value(EV) | 9,306.48 Cr. | 2022-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 29.87 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | 22.93 | Trailing Twelve Months Ending 2022-03 |
Industry PE | 28.07 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | 140.36 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | 4.88 | Calculated using Price: 685.05 |
Dividend Yield | 0.80 | Period Ending 2021-03 |
No. of Shares Subscribed | 13.60 Cr. | 135,957,963 Shares |
FaceValue | 1 | |
Company Profile | ||
Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company’s focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors. Eris features amongst the Top 30 companies in the Indian Branded Formulations Market. The company’s core commitment is towards improving health care outcomes and adding value for all its stakeholders including patients, doctors, regulators, employees and business partners. The company is making ongoing efforts to innovate its products to bring the best clinical practices in health care industry to its customers. The company’s product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists. Business area of the company The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders. History and milestones
|
1 Day |
|
+0.96% |
1 Week |
|
-2.39% |
1 Month |
|
-0.86% |
3 Month |
|
+4.96% |
6 Month |
|
-8.05% |
1 Year |
|
-3.13% |
2 Year |
|
+39.75% |
5 Year |
|
|
10 Year |
|
9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 75.91 | 50.12 | 40.30 | 47.68 | 56.90 | 41.30 | 28.96 | 24.28 | 24.78 | |
Return on Capital Employed (%) | 103.88 | 68.93 | 49.25 | 54.56 | 62.56 | 35.76 | 26.54 | 25.44 | 27.60 | |
Return on Assets (%) | 42.75 | 32.09 | 28.59 | 36.17 | 43.89 | 27.31 | 20.02 | 20.33 | 22.62 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
Shh. Funds | 106 | 177 | 266 | 300 | 567 | 861 | 1,151 | 1,296 | 1,576 | 1,908 | |
Non Curr. Liab. | 17 | 18 | 19 | 20 | 12 | 248 | -66 | -80 | -109 | -79 | |
Curr. Liab. | 44 | 71 | 65 | 69 | 129 | 294 | 377 | 220 | 235 | 200 | |
Minority Int. | 5 | 4 | 4 | 3 | 24 | 25 | 18 | 0 | |||
Equity & Liab. | 172 | 270 | 354 | 392 | 732 | 1,428 | 1,481 | 1,437 | 1,703 | 2,029 | |
Non Curr. Assets | 45 | 115 | 191 | 169 | 463 | 1,061 | 827 | 902 | 1,167 | 1,402 | |
Curr. Assets | 126 | 155 | 163 | 222 | 270 | 367 | 653 | 535 | 536 | 627 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 172 | 270 | 354 | 392 | 732 | 1,428 | 1,481 | 1,437 | 1,703 | 2,029 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
Net Sales | 393 | 509 | 546 | 597 | 750 | 856 | 982 | 1,074 | 1,212 | 1,347 | |
Other Income | 1 | 4 | 3 | 3 | 25 | 26 | 32 | 16 | 9 | 26 | |
Total Income | 395 | 513 | 549 | 600 | 775 | 882 | 1,014 | 1,090 | 1,221 | 1,373 | |
Total Expenditure | -307 | -410 | -424 | -425 | -480 | -533 | -637 | -706 | -781 | -862 | |
PBIDT | 87 | 103 | 125 | 175 | 294 | 349 | 377 | 384 | 439 | 511 | |
Interest | -1 | 0 | 0 | 0 | -1 | -11 | -23 | -2 | -2 | -4 | |
Depreciation | -3 | -5 | -16 | -20 | -23 | -26 | -36 | -50 | -43 | -65 | |
Taxation | -25 | -27 | -20 | -20 | -24 | -17 | -26 | -35 | -39 | -36 | |
Exceptional Items | |||||||||||
PAT | 58 | 71 | 89 | 135 | 247 | 295 | 291 | 297 | 355 | 406 | |
Minority Interest | 0 | 0 | 0 | -1 | 0 | -1 | 0 | 0 | 0 | ||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 58 | 71 | 89 | 134 | 247 | 294 | 291 | 297 | 355 | 406 | |
Adjusted EPS | 4,217 | 5,130 | 6,466 | 9,679 | 18 | 21 | 21 | 22 | 26 | 30 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 30 | 38 | 90 | 90 | 131 | 200 | 235 | 223 | 271 | 375 | |
Cash Fr. Inv. | -19 | -36 | -83 | -92 | -44 | -184 | -590 | -5 | 123 | -323 | |
Cash Fr. Finan. | -10 | -3 | -2 | 0 | -84 | -24 | 363 | -221 | -335 | -82 | |
Net Change | 1 | -1 | 5 | -2 | 4 | -8 | 8 | -3 | 60 | -30 | |
Cash & Cash Eqvt | 3 | 2 | 7 | 5 | 9 | 2 | 11 | 8 | 67 | 37 |
Wed, 18 May 2022
CORPORATE PRESENTATION Dear Sir/Madam Pursuant to the requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find attached corporate presentation made by the Company. |
Tue, 17 May 2022
UPDATE ON ACQUISTION OF OAKNET HEALTHCARE PRIVATE LIMITED We refer to our earlier intimation dated 04th May 2022 for acquisition of Oaknet Healthcare Private Limited.We now wish to inform that the transaction has achieved closure.This is for you information and record. |
Tue, 10 May 2022
Announcement under Regulation 30 (LODR)-Earnings Call Transcript TRANSCRIPT OF ANALYST AND INVESTOR CALL |
Wed, 25 May 2022 |
|
|
|
|
Tue, 24 May 2022 |
|